Actively Recruiting
CorEvitas Systemic Lupus Erythematosus (SLE) Drug Safety and Effectiveness Registry
Led by CorEvitas · Updated on 2026-02-06
1000
Participants Needed
1
Research Sites
3927 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Prospective, observational registry for subjects with SLE under the care of a rheumatology provider. Longitudinal data are collected from both subjects and their treating rheumatology provider during routine clinical encounters using a structured and standardized data collection method.
CONDITIONS
Official Title
CorEvitas Systemic Lupus Erythematosus (SLE) Drug Safety and Effectiveness Registry
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with Systemic Lupus Erythematosus (SLE) by a rheumatologist or qualified rheumatology practitioner
- At least 18 years old and legally able to consent
- Willing and able to provide informed consent
- Willing and able to provide personal identifying information if required
- Have at least one of the following: new SLE diagnosis within 12 months, starting biologic or immunosuppressant treatment for SLE at enrollment, or Lupus Nephritis (class III-V) diagnosed within 2 years
You will not qualify if you...
- Participating in a double-blind clinical trial for an SLE drug
- Participating in any non-blinded clinical trial except for non-blinded CAR-T or other cell/gene therapies for SLE
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CorEvitas
Waltham, Massachusetts, United States, 02451
Actively Recruiting
Research Team
C
CorEvitas, LLC
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here